Gustave Roussy, Cancer Campus, Grand Paris

This early-stage study aimed to see if it was safe to add a new immunotherapy drug called durvalumab to a standard three-drug chemotherapy regimen for patients with advanced head and neck cancer that had not spread. The main goal was to find the safest dose for future testing and…

This study tested whether combining two drugs, niraparib and dostarlimab, could help control advanced cancers that had specific genetic problems or were previously sensitive to platinum chemotherapy. It involved 51 adults with various cancers, including bladder, stomach, and kidn…

This study aimed to find a better way to treat children with very high-risk neuroblastoma, a serious childhood cancer, when standard first treatments don't work well. It compared two different sequences of powerful chemotherapy and stem cell transplants. The goal was to see which…

This trial tested whether combining two existing cancer drugs—rucaparib and atezolizumab—could better control advanced solid tumors. It enrolled 130 adults with specific cancers, like lung or bladder cancer, that had certain genetic repair problems or were sensitive to platinum c…

This study tested whether a short course of immunotherapy drugs, given just before standard surgery or chemotherapy, could boost the immune system's attack on early-stage breast cancer. Researchers measured changes in specific immune cells in tumor samples taken before and after …